SEC Form 10-K filed by Dollar Tree Inc.
$DLTR
Department/Specialty Retail Stores
Consumer Discretionary
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/27/2025 | $75.00 → $82.00 | Market Perform | Telsey Advisory Group |
| 11/7/2024 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 11/5/2024 | $95.00 → $75.00 | Outperform → Market Perform | Telsey Advisory Group |
| 10/22/2024 | $76.00 | Mkt Perform | Bernstein |
| 9/5/2024 | $120.00 → $95.00 | Outperform | Telsey Advisory Group |
| 9/5/2024 | $65.00 | Buy → Hold | Loop Capital |
| 9/5/2024 | $130.00 → $68.00 | Outperform → Market Perform | BMO Capital Markets |
| 9/4/2024 | $111.00 → $70.00 | Overweight → Neutral | JP Morgan |
Review of Strategic Alternatives Concludes with Agreement to Sell Family Dollar Family Dollar Fourth Quarter and Full-Year Fiscal 2024 Results Are Reported as Discontinued Operations Dollar Tree Same-Store Net Sales +2.0% on +0.7% Traffic and +1.3% Ticket Diluted Loss per Share of $17.17 and Diluted Earnings per Share (EPS) from Continuing Operations of $1.86 Adjusted Diluted EPS of $2.29, Including $2.11 from Continuing Operations and $0.18 from Discontinued Operations Full-Year Fiscal 2025 Outlook Ranges of $18.5 to $19.1 Billion for Net Sales and $5.00 to $5.50 for Adjusted EPS from Continuing Operations, Including $0.30 to $0.35 Negative Impact from Having Only Half-Year Bene
Transaction completes previously announced review of Strategic Alternatives for Family Dollar Business Dollar Tree, Inc. (NASDAQ:DLTR) today announced that the Company has reached an agreement under which Brigade Capital Management, LP ("Brigade") and Macellum Capital Management, LLC ("Macellum") will partner to acquire the Company's Family Dollar business segment. Family Dollar will remain headquartered in Chesapeake, Virginia. The purchase price for Family Dollar, under the terms of the agreement, is $1,007.0 million, subject to customary closing adjustments. After a thorough review of potential alternatives for the Family Dollar business segment, the Dollar Tree leadership team and
Dollar Tree announces that Stewart Glendinning will become the Company's next Chief Financial Officer, effective March 30, 2025 Company announces date for fourth quarter earnings conference call Dollar Tree, Inc. (NASDAQ:DLTR) today announced that Stewart Glendinning will become the Company's next Chief Financial Officer (CFO), effective March 30, 2025. Mr. Glendinning joined Dollar Tree earlier this year in a senior role focused on enterprise-wide transformation initiatives, including key areas within the Company's finance organization and the review of strategic alternatives for the Family Dollar business. Mr. Glendinning will succeed Jeff Davis, who previously announced plans to s
8-K - DOLLAR TREE, INC. (0000935703) (Filer)
8-K - DOLLAR TREE, INC. (0000935703) (Filer)
10-K - DOLLAR TREE, INC. (0000935703) (Filer)
Review of Strategic Alternatives Concludes with Agreement to Sell Family Dollar Family Dollar Fourth Quarter and Full-Year Fiscal 2024 Results Are Reported as Discontinued Operations Dollar Tree Same-Store Net Sales +2.0% on +0.7% Traffic and +1.3% Ticket Diluted Loss per Share of $17.17 and Diluted Earnings per Share (EPS) from Continuing Operations of $1.86 Adjusted Diluted EPS of $2.29, Including $2.11 from Continuing Operations and $0.18 from Discontinued Operations Full-Year Fiscal 2025 Outlook Ranges of $18.5 to $19.1 Billion for Net Sales and $5.00 to $5.50 for Adjusted EPS from Continuing Operations, Including $0.30 to $0.35 Negative Impact from Having Only Half-Year Bene
Dollar Tree announces that Stewart Glendinning will become the Company's next Chief Financial Officer, effective March 30, 2025 Company announces date for fourth quarter earnings conference call Dollar Tree, Inc. (NASDAQ:DLTR) today announced that Stewart Glendinning will become the Company's next Chief Financial Officer (CFO), effective March 30, 2025. Mr. Glendinning joined Dollar Tree earlier this year in a senior role focused on enterprise-wide transformation initiatives, including key areas within the Company's finance organization and the review of strategic alternatives for the Family Dollar business. Mr. Glendinning will succeed Jeff Davis, who previously announced plans to s
Same-Store Net Sales: Dollar Tree +1.8%; Family Dollar +1.9%; Enterprise +1.8% Diluted Earnings per Share (EPS) of $1.08 and Adjusted Diluted EPS of $1.12 Fourth Quarter Fiscal 2024 Net Sales Outlook Range of $8.1 Billion to $8.3 Billion Fourth Quarter Fiscal 2024 Adjusted Diluted EPS Outlook Range of $2.10 to $2.30 Full-Year Fiscal 2024 Net Sales Outlook Range of $30.7 Billion to $30.9 Billion Full-Year Fiscal 2024 Adjusted Diluted EPS Outlook Range of $5.31 to $5.51 Family Dollar Review of Strategic Alternatives Remains on Track Announces Chief Financial Officer Transition Dollar Tree, Inc. (NASDAQ:DLTR) today reported financial results for its third quarter ended
3 - DOLLAR TREE, INC. (0000935703) (Issuer)
3 - DOLLAR TREE, INC. (0000935703) (Issuer)
3 - DOLLAR TREE, INC. (0000935703) (Issuer)
4 - DOLLAR TREE, INC. (0000935703) (Issuer)
4 - DOLLAR TREE, INC. (0000935703) (Issuer)
4 - DOLLAR TREE, INC. (0000935703) (Issuer)
Telsey Advisory Group reiterated coverage of Dollar Tree with a rating of Market Perform and set a new price target of $82.00 from $75.00 previously
KeyBanc Capital Markets downgraded Dollar Tree from Overweight to Sector Weight
Telsey Advisory Group downgraded Dollar Tree from Outperform to Market Perform and set a new price target of $75.00 from $95.00 previously
Dollar Tree, Inc. (NASDAQ:DLTR) today announced that effective immediately, William (Bill) W. Douglas, III and Timothy (Tim) Johnson have been appointed to the Company's Board of Directors. In addition, Chief Executive Officer Michael C. Creedon, Jr. has joined the Board. "Bill and Tim are both esteemed financial leaders with a strong understanding of today's competitive retail landscape," said CEO Mike Creedon. "We look forward to their many contributions and support in driving long-term value for our associates, customers, and shareholders." Chairman of the Board Edward (Ned) J. Kelly, III stated, "The additions of Bill, Tim, and Mike complement our current Board of Directors' skillse
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that AppLovin Corporation (NASDAQ:APP), will become a component of the Nasdaq-100 Index® (NASDAQ:NDX) and the Nasdaq-100 Equal Weighted™ Index (NASDAQ:NDXE) prior to market open on Monday, November 18, 2024. AppLovin Corporation will replace Dollar Tree, Inc. (NASDAQ:DLTR) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted™ Index. Dollar Tree, Inc. will also be removed from the Nasdaq-100 Ex-Tech Sector™ Index (NASDAQ:NDXX), the Nasdaq-100 ESG™ Index (NASDAQ:NDXESG), the Nasdaq-100 Sustainable ESG Select™ Index (NASDAQ:NDXSES) , the Nasdaq-100 ex Top 30™ Index (NASDAQ:NDX), and the Nasdaq-100 ex T
Michael C. Creedon Jr. Appointed Interim Chief Executive Officer Edward J. Kelly, III Elected Chairman Company Reaffirms Fiscal Third Quarter 2024 Outlook Review of Strategic Alternatives for Family Dollar Progressing Dollar Tree, Inc. (NASDAQ:DLTR) today announced that Rick Dreiling has stepped down from his position as Chairman and Chief Executive Officer, effective as of Nov. 3, 2024. Michael C. Creedon Jr., Chief Operating Officer, has been appointed Interim Chief Executive Officer while Edward (Ned) J. Kelly, III, Lead Independent Director, has been elected Chairman. The Board is conducting a search process to identify a permanent CEO, which will include internal and external
SC 13G/A - DOLLAR TREE, INC. (0000935703) (Subject)
SC 13G/A - DOLLAR TREE, INC. (0000935703) (Subject)
SC 13G/A - DOLLAR TREE, INC. (0000935703) (Subject)
For Immediate Release: June 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced a request for input about patient safety associated with certain medical software functions excluded from the medical device definition. This input will help the FDA develop the 2024 report on the risks and benefits to health of non-devic